The Society for Neuroscience annual meeting, which took place last week in Chicago, IL, is a place where the latest preliminary data in neuroscience is presented. True to form, there was an interesting abstract presented by Fernando Pagan, M.D. and colleagues from Georgetown University Hospital which suggested a potential treatment for those with Parkinson’s disease (PD). At the heart of the presentation, Dr. Pagan and colleagues reported that in a small trial, an anti-cancer drug called nilotinib was able to reverse both the movement symptoms and cognitive decline of people with PD involved in the study.
Articles by this Author:
The start of 2015 has been noteworthy for those with Parkinson’s disease (PD) as two new therapies – Rytary™ and Duopa™ – were approved by the FDA at the start of January. Both therapies are updates to the gold-standard treatment of carbidopa/levodopa for those with PD. Manufacturers of both therapies hope to have the medications available on pharmacy shelves in the next few months. Yes, carbidopa/levodopa first came into use around 1970. However, these new therapies address a real need that current carbidopa/levodopa or Sinemet cannot meet … and that is good news. PDF has covered what Rytary and Duopa are (check out my… Read More
The recent ice bucket challenge that has raised awareness and funds for ALS has been a huge success. What may have been overshadowed by this success is the reporting of the first solid estimate of how many people in the United States live with ALS – 12,187. It may seem like a small number but it helps many – from families to policy makers – understand what we are up against in solving that disease. While the estimates of people living with Parkinson’s disease are much larger than for those with ALS, the fact of the matter is that our community does not exactly know the… Read More
The Parkinson’s Disease Foundation has long recognized the creative abilities that many people with Parkinson’s disease acquire when living with the disease. We even capture many of these expressions on our website with some of the best examples appearing in our acclaimed annual calendar (which you can now pre-order for 2015 here).
Nearly two years ago, I wrote about how the US Food and Drug Administration (FDA) appeared to be ready to approve a new drug for neurogenic orthostatic hypotension (NOH), which, basically, is a precipitous drop in blood pressure upon standing. (I recommend reading that blog as a good primer.) That drug, droxidopa with the brand name of Northera™, did not win approval because of outstanding concerns by FDA. Fast-forward to this week, and FDA has now signaled that it will approve droxidopa for the treatment of NOH.
The effort to cure diseases like Parkinson’s disease is on the minds of many people during this time of year. We are often traveling home to see loved ones where we learn about new diagnoses or new stages in the disease that they battle, or we are remembering those who bravely fought their battle with Parkinson’s, yet lost. It is understandable, therefore, why there is a push to fund only research that is the closest to bringing about a cure, so-called translational research.